Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Mar;23(1):614-621.
doi: 10.4314/ahs.v23i1.65.

Ginger supplementation for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Affiliations
Meta-Analysis

Ginger supplementation for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Qun Zhou et al. Afr Health Sci. 2023 Mar.

Abstract

Introduction: The efficacy of ginger supplementation remains controversial for non-alcoholic fatty liver disease. We conduct this meta-analysis to explore the influence of ginger supplementation versus placebo on the treatment of non-alcoholic fatty liver disease.

Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through November 2021 and included randomized controlled trials (RCTs) assessing the efficacy of ginger supplementation versus placebo for non-alcoholic fatty liver disease. This meta-analysis was performed using the random-effect model.

Results: Four RCTs involving 177 patients were included in the meta-analysis. Overall, compared with non-alcoholic fatty liver disease, ginger supplementation was associated with significantly reduced alanine aminotransferase (ALT, standard mean difference (SMD)=-0.43; 95% confidence interval [CI]=-0.85 to -0.02; P=0.04), homeostatic Model Assessment of Insulin Resistance (HOMA-IR, SMD=-1.14; 95% CI=-2.05 to -0.22; P=0.02), but revealed no obvious impact on aspartate-aminotransferase (AST, SMD=-0.66; 95% CI=-0.81 to 2.12; P=0.38), total cholesterol (SMD=-0.33; 95% CI=-0.67 to 0.02; P=0.06), low density lipoprotein (LDL, SMD=-0.30; 95% CI=-0.64 to 0.04; P=0.08) or body mass index (BMI, SMD=0; 95% CI=-0.41 to 0.40; P=0.99).

Conclusions: Ginger supplementation benefits to treat non-alcoholic fatty liver disease.

Keywords: ginger; meta-analysis; non-alcoholic fatty liver disease; randomized controlled trials.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Flow diagram of study searching and selection process.
Figure 2
Figure 2
Forest plot for the meta-analysis of ALT.
Figure 3
Figure 3
Forest plot for the meta-analysis of AST.
Figure 4
Figure 4
Forest plot for the meta-analysis of HOMA-IR
Figure 5
Figure 5
Forest plot for the meta-analysis of total cholesterol.
Figure 6
Figure 6
Forest plot for the meta-analysis of LDL.
Figure 7
Figure 7
Forest plot for the meta-analysis of BMI.

References

    1. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. Journal of hepatology. 2019;70(3):531–544. - PubMed
    1. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (Baltimore, Md.) 2009;49(1):306–317. - PMC - PubMed
    1. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC medicine. 2017;15(1):45. - PMC - PubMed
    1. Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update, Metabolism. clinical and experimental. 2016;65(8):1109–1123. - PubMed
    1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (Baltimore, Md.) 2003;37(4):917–923. - PubMed

Publication types

LinkOut - more resources